SlideShare a Scribd company logo
1 of 9
Download to read offline
EW
PR
EV
I

BRAZIL
Brazil
Clinical Development
Profile

Info@ISRreports.com 	
	

	

©2014 Industry Standard Research

www.ISRreports.com
act with confidence

Report Overview
In this report, ISR provides insight into the clinical trial regulation and development environment, sponsor and
service provider activities, and population “health status” for Brazil.

Methodologies:
ISR gathered content for this report via an exhaustive secondary research effort and from company profile
questionnaires that were distributed to CROs profiled in this report.

56

Charts and Graphs

Q1,
2014

Report Structure:
1. Introduction
2. Brazilian Health Statistics
3. Clinical Trial Overview and Trial Metrics
4. Profile of Domestic Clinical Service Providers
5. Brazil Pharma/CRO Associations
6. International CROs Operating in Brazil

Publication Date

79

Pages

Valuable for:
Clinical Operations, Medical Directors, Patient Recruitment,
Site Selection, Portfolio Management

What you will learn in this report:
•	 How population health status, regulations
and clinical trial activity, and international
and domestic company partnerships make
Brazil one of the top emerging global
pharmaceutical markets
•	 Insights from domestic service provider

organizations on conducting clinical trials
in Brazil
•	 Clinical trial operational metrics for Brazil-only
clinical studies
•	 Compiled lists and contact details for domestic
and international service providers in Brazil

How you can use this report:
•	 Understand how Brazil compares to other
countries on a variety of health condition
scales so the reader can best consider the
areas in which Brazil may be beneficial as a
trail site

•	 Understand the legal, logistical, and regulatory
details for conducting Brazilian trials, and
illustrate the benefits and drawbacks of
conducting trials in Brazil

NEXT: Table of Contents and Sample Pages
www.ISRreports.com ©2014 | Preview of: Brazil Clinical Development Profile

2
act with confidence

Table of Contents
For table of contents and additional sample pages, download the full preview
from our website:
http://www.isrreports.com/product/brazil-clinical-development-profile/

www.ISRreports.com ©2014 | Preview of: Brazil Clinical Development Profile

3
act with confidence

Sample Page
Introduction

act with confidence

Introduction
Brazil’s population is approximately 200 million and represents enormous potential for the
Welcome to ISR’s second Investigator Payments report highlighting Europe’s clinical
pharmaceutical industry. The country is beginning to build a better understanding of clinical
trial compensation. In this report, ISR wanted to gain a reputation for high-quality
trials and biodiversity, and is attracting multinational pharmaceutical companies as it continues
what drives investigator payments so that sponsors and CROs can benchmark their
to develop its domestic providers as well.
payment levels and better plan for study costs.
According to IMS Health’s Medicines Outlook Through 2016 Report, the pharmaceutical marDeterminants of investigator payments come in many forms such as therapeutic
ket in Brazil has experienced, on average, a 15.6% compound annual growth rate (CAGR) from
area, compound orientation, trial complexity, and patient needs. Is there a one-size2007-2011. IMS forecasts that Brazil will experience a CAGR of 12-15% from 2012-2016. It is
fits-all formula that can be applied uniformly across studies to produce the most
also estimated that Brazil’s pharmaceutical spend per capita will be $180.
effective compensation plan? Perhaps not, but by using this array of compensation
averages pharmaceutical personnel and by understanding their non-monetary
The Brazilianprovided by site market does pose a number of challenges due to its diverse
motivations for for participation, planning to a sponsor or CRO can recruit and
nature. A challengetrial foreign playersISR believes enter the market is the legal framework of
the country. This forces thewithout breaking the budget. local companies, resulting in profit
retain high quality sites companies into partnering with
and control sharing. The legal and regulatory framework for patents is limited, leading to a lack
of protection for intellectual property rights.
In the process of writing this report, ISR reached out the CROs profiled in this report. Questionnaires were sent to contacts within these companies that asked questions regarding the company’s profile, the benefits and shortcomings of conducting trials in Brazil, and trends they’ve
noticed in those planning to outsource clinical studies in Brazil. Not all of the CROs profiled in
this report provided answers to the questionnaire that was sent.
The complete responses from the CROs that responded are included in their entirety in this report. However, there were a few trends ISR noticed in the responses that we believe are worth
highlighting in this portion of the report. Primarily, ISR noticed that regulatory related concerns
are the primary concerns respondents voiced with regard to conducting clinical trials in Brazil.
The question posed by ISR was: “What are the challenges in conducting a trial in Brazil?” Some
of the responses received are shown below:
“The main challenge is to improve regulatory submission timelines.”
“Regulatory approvals timing”
“The current regulatory scenario shows that depending on the project type it could take
around 7-9 months for having the study approved by all required regulatory agencies
(CEP, CONEP and ANVISA).”
Timeline issues are typically a main concern in clinical research and, within the Brazilian
contract research market, regulatory issues are a major factor contributing to timeline delays.
Respondents from the domestic Brazilian CROs realize regulatory delays associated with conducting clinical trials in Brazil are substantial and often reach out to clients to make them aware
of the delays that could be experienced.

www.ISRreports.com ©2014 | Benchmarking European Investigator Payments

6

www.ISRreports.com ©2014 | Preview of: Brazil Clinical Development Profile

This is a site-wide license and this file is not to be distributed beyond the terms of this agreement. For information on the license holder, please contact ISR (info@ISRreports.com).

4
act with confidence

Sample Page
Brazil Health Statistics

act with confidence

Female breast cancer incidence

Female breast cancer incidence

The following chart, from the Health at a Glance OECD 2011 report, shows ageThe following chart, from the Health at a Glance OECD 2011 report, shows age-standardized female
standardized incidence rates, 2009 (or nearest year). Brazil reports a rate of 42.3
breast cancer female breast cancer incidence rates, 2009 (or nearest year)� Brazil per 100,000 females.
This number isof 42�3 than100,000 females� This 71.6.
reports a rate lower per the OECD average of number is lower than the OECD
average of 71�6�
109.4

Belgium
France
Israel
Netherlands
Ireland
New Zealand
Switzerland
Denmark
United Kingdom
Finland
Italy
Iceland
Australia
Canada
Sweden
Luxembourg
Germany
Norway
United States
OECD
Austria
Czech Republic
Slovenia
Spain
Portugal
Hungary
Slovak Republic
Estonia
Poland
Greece
Russian Federation
Japan
Brazil
South Africa
Chile
Korea
Indonesia
Turkey
Mexico
India
China

99.7
96.8
96.8
93.9
89.4
89.4
89.1
87.9
86.6
86.3
86.2
84.8
83.2
82.7
82.3
81.8
76.2
76.0
71.6
69.9
67.7
65.5
61.0
60.0
57.9
53.4
50.2
48.9
44.9
43.2
42.7
42.3
41.0
40.1
38.9
36.2
28.3
27.2
22.9
21.6
©2014 Industry Standard Research

0

20
40
60
80
100
Age-standardized rates per 100,000 population

120

www.ISRreports.com ©2014 | Brazil: Clinical Development Profile

13

www.ISRreports.com ©2014 | Preview of: Brazil Clinical Development Profile
This is an enterprise-wide license and this file is not to be distributed beyond the terms of this agreement. For information on the license holder, please contact ISR (info@ISRreports.com).

5
act with confidence

Sample Page
Clinical Trial Overview

act with confidence

Regulatory overview
According to SOMO’s Putting Contract Research Organisations on the Radar, the
Brazilian regulatory agency ANVISA or Agência Nacional de Vigilância Sanitária (the
Brazilian equivalent of the United States FDA) changed the regulatory process to
expedite the regulatory approval of multicenter clinical trials in 2009� Today, only local
Putting Contract of the coordinator sites have to
ethics committeesResearch Organisations on the Radarapprove the study instead of all
local ethics committees that have jurisdiction over each investigative site involved�
After this approval is granted, the National Ethics Committee (CONEP) and ANVISA are
approached simultaneously for approval� ANVISA is also the agency that gives approval
for importation�
The choice of on coordinator site is no crucial as requirements to disclose the
SOMO also goes the to reveal there arenowregulatory the approval for all investigators sites is now in
the hands the contracts between the sponsors of the study and new legislation
conditions of of one local ethics committee. If used appropriately, thethe CROs, or should not
weaken the protection of clinical trial investigators, to the ethics interview, a member of the
between the sponsors and the principalparticipants. However, in an committees�
National Ethics to the conditions but it is not used emphasised the need to
ANVISA has accessCommission expressed concern and to evaluate whether the monitor the
125
implementation of the new process. The interviews with CROs indicate
contractual arrangements protect the rights of the research participants� that the speed of
proposal approval by the ethics committees is an important decisive factor in selecting the
126
coordinating centre.
SOMO’s Brazil regulatory flowchart
Figure 5: Regulatory flowchart – Brazil

Source: Business Insights.

127

Source: SOMO

The first Brazilian regulation that mentions the word CRO (known as ORCP in Brazil) is the RDC
number 39, which was approved on 5 July 2008. This regulation defines the concept of CRO and
its obligations. Like in Argentina, the only requirement is that the Clinical Development Profile to operate,
www.ISRreports.com ©2014 | Brazil: CROs obtain a license
27
as any other health provider. ANVISA does not register a CRO until they present a project to the
www.ISRreports.com ©2014 | Preview of: Brazil Clinical Development Profile
regulatory agency.
This is an enterprise-wide license and this file is not to be distributed beyond the terms of this agreement. For information on the license holder, please contact ISR (info@ISRreports.com).

Contrary to the situation in Argentina, there is no obligation to disclose the conditions of the

6
act with confidence

Sample Page
For table of contents and additional sample pages, download the full preview
from our website:
http://www.isrreports.com/product/brazil-clinical-development-profile/

www.ISRreports.com ©2014 | Preview of: Brazil Clinical Development Profile

7
act with confidence

Ordering Information
For pricing and ordering information, please visit our website:
http://www.isrreports.com/product/brazil-clinical-development-profile/

Save on this,
or any ISR
report, by
registering a
free account

Register now
•	 Receive a $250 instant credit towards any ISR report
•	 Earn 10% credit towards all future purchases
•	 Receive advanced notifications on ISR’s latest reports and free resources

About Industry Standard Research
Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services industries.  With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise. 
 
For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at www.
ISRreports.com, email info@ISRreports.com, or follow us on twitter @ISRreports.
www.ISRreports.com ©2014 | Preview of: Brazil Clinical Development Profile

8
The ISR Difference

act with confidence

Custom-quality syndicated market research
www.ISRreports.com

ISR's Reports

vs.

The Common
Syndicated Report

How confident are you?
Research methods
Mostly primary
research;
always appropriate
for the topic

vs.
vs.

One size fits all;
usually publically
available data

Data Collection
ISR's proprietary data collection
tools and channels support fast,
high quality data collection

vs.

Struggle to recruit the right
targets and enough of them

Respondents
Sophisticated screening
ensures genuine
decision-makers

vs.

Undisclosed
methodologies and
respondent demographics

Sample Sizes

Robust sample sizes that
instill confidence

vs.

Often insufficient industry
representation that leaves you
defending results

Analysts
Decades of experience
means more insights that are
immediately usable

vs.
vs.

Junior analysts capable of
reporting numbers

www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Profile
www.ISRreports.com ©2014 | Preview of: Brazil Clinical Development Functions 9

More Related Content

More from Industry Standard Research

Infographic: The World of Drug Development Trends
Infographic: The World of Drug Development TrendsInfographic: The World of Drug Development Trends
Infographic: The World of Drug Development TrendsIndustry Standard Research
 
Infographic: eClinical Trends, Tips, and Technology
Infographic: eClinical Trends, Tips, and TechnologyInfographic: eClinical Trends, Tips, and Technology
Infographic: eClinical Trends, Tips, and TechnologyIndustry Standard Research
 
EDC and eCOA/ePRO Market Dynamics and Service Provider Performance (2015)
EDC and eCOA/ePRO Market Dynamics and Service Provider Performance (2015)EDC and eCOA/ePRO Market Dynamics and Service Provider Performance (2015)
EDC and eCOA/ePRO Market Dynamics and Service Provider Performance (2015)Industry Standard Research
 
Infographic: Thyroid Cancer: Disease and Pipeline Analysis
Infographic: Thyroid Cancer:  Disease and Pipeline AnalysisInfographic: Thyroid Cancer:  Disease and Pipeline Analysis
Infographic: Thyroid Cancer: Disease and Pipeline AnalysisIndustry Standard Research
 
Benchmarking the Pharma Industry’s Medical Affairs Functions
Benchmarking the Pharma Industry’s Medical Affairs FunctionsBenchmarking the Pharma Industry’s Medical Affairs Functions
Benchmarking the Pharma Industry’s Medical Affairs FunctionsIndustry Standard Research
 
Clinical development activity in perspective: A head-to-head comparison of ...
Clinical development activity in perspective: A head-to-head comparison of ...Clinical development activity in perspective: A head-to-head comparison of ...
Clinical development activity in perspective: A head-to-head comparison of ...Industry Standard Research
 
Brain Cancer (Glioblastoma Multiforme): Profile & Drug Development
Brain Cancer (Glioblastoma Multiforme): Profile & Drug DevelopmentBrain Cancer (Glioblastoma Multiforme): Profile & Drug Development
Brain Cancer (Glioblastoma Multiforme): Profile & Drug DevelopmentIndustry Standard Research
 
What does the future hold for Detailing and drug reps?
What does the future hold for Detailing and drug reps?What does the future hold for Detailing and drug reps?
What does the future hold for Detailing and drug reps?Industry Standard Research
 
Advocacy Groups: Enhancing Relationships and Patient Recruitment
Advocacy Groups: Enhancing Relationships and Patient RecruitmentAdvocacy Groups: Enhancing Relationships and Patient Recruitment
Advocacy Groups: Enhancing Relationships and Patient RecruitmentIndustry Standard Research
 
EMRs and Clinical Research: Current and Potential Impact
EMRs and Clinical Research: Current and Potential ImpactEMRs and Clinical Research: Current and Potential Impact
EMRs and Clinical Research: Current and Potential ImpactIndustry Standard Research
 

More from Industry Standard Research (20)

Infographic: The World of Drug Development Trends
Infographic: The World of Drug Development TrendsInfographic: The World of Drug Development Trends
Infographic: The World of Drug Development Trends
 
Infographic: eClinical Trends, Tips, and Technology
Infographic: eClinical Trends, Tips, and TechnologyInfographic: eClinical Trends, Tips, and Technology
Infographic: eClinical Trends, Tips, and Technology
 
EDC and eCOA/ePRO Market Dynamics and Service Provider Performance (2015)
EDC and eCOA/ePRO Market Dynamics and Service Provider Performance (2015)EDC and eCOA/ePRO Market Dynamics and Service Provider Performance (2015)
EDC and eCOA/ePRO Market Dynamics and Service Provider Performance (2015)
 
Orphan Drug 101
Orphan Drug 101Orphan Drug 101
Orphan Drug 101
 
Infographic: Ovarian Cancer Profile
Infographic: Ovarian Cancer ProfileInfographic: Ovarian Cancer Profile
Infographic: Ovarian Cancer Profile
 
Infographic: CRO Capital Market
Infographic: CRO Capital MarketInfographic: CRO Capital Market
Infographic: CRO Capital Market
 
2014 Clinical Development Year in Review
2014 Clinical Development Year in Review2014 Clinical Development Year in Review
2014 Clinical Development Year in Review
 
Infographic: Thyroid Cancer: Disease and Pipeline Analysis
Infographic: Thyroid Cancer:  Disease and Pipeline AnalysisInfographic: Thyroid Cancer:  Disease and Pipeline Analysis
Infographic: Thyroid Cancer: Disease and Pipeline Analysis
 
Benchmarking the Pharma Industry’s Medical Affairs Functions
Benchmarking the Pharma Industry’s Medical Affairs FunctionsBenchmarking the Pharma Industry’s Medical Affairs Functions
Benchmarking the Pharma Industry’s Medical Affairs Functions
 
Bladder Cancer: profile and drug development
Bladder Cancer: profile and drug developmentBladder Cancer: profile and drug development
Bladder Cancer: profile and drug development
 
Clinical development activity in perspective: A head-to-head comparison of ...
Clinical development activity in perspective: A head-to-head comparison of ...Clinical development activity in perspective: A head-to-head comparison of ...
Clinical development activity in perspective: A head-to-head comparison of ...
 
[Infographic] Lung Cancer
[Infographic] Lung Cancer[Infographic] Lung Cancer
[Infographic] Lung Cancer
 
Brain Cancer (Glioblastoma Multiforme): Profile & Drug Development
Brain Cancer (Glioblastoma Multiforme): Profile & Drug DevelopmentBrain Cancer (Glioblastoma Multiforme): Profile & Drug Development
Brain Cancer (Glioblastoma Multiforme): Profile & Drug Development
 
Clinical Development Year in Review (2013)
Clinical Development Year in Review (2013)  Clinical Development Year in Review (2013)
Clinical Development Year in Review (2013)
 
What does the future hold for Detailing and drug reps?
What does the future hold for Detailing and drug reps?What does the future hold for Detailing and drug reps?
What does the future hold for Detailing and drug reps?
 
The ISR Difference
The ISR DifferenceThe ISR Difference
The ISR Difference
 
Biosimilar Education
Biosimilar EducationBiosimilar Education
Biosimilar Education
 
Advocacy Groups: Enhancing Relationships and Patient Recruitment
Advocacy Groups: Enhancing Relationships and Patient RecruitmentAdvocacy Groups: Enhancing Relationships and Patient Recruitment
Advocacy Groups: Enhancing Relationships and Patient Recruitment
 
EMRs and Clinical Research: Current and Potential Impact
EMRs and Clinical Research: Current and Potential ImpactEMRs and Clinical Research: Current and Potential Impact
EMRs and Clinical Research: Current and Potential Impact
 
The Landscape of the Biosimilar Market
The Landscape of the Biosimilar MarketThe Landscape of the Biosimilar Market
The Landscape of the Biosimilar Market
 

Recently uploaded

Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxkitati1
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxLikeways
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
General_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingGeneral_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingAnonymous
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisNilofarRasheed1
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 

Recently uploaded (20)

Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptx
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
Cone beam CT: concepts and applications.pptx
Cone beam CT: concepts and applications.pptxCone beam CT: concepts and applications.pptx
Cone beam CT: concepts and applications.pptx
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
General_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingGeneral_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_Wellbeing
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid Arthritis
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 

Brazil: Clinical Development Profile

  • 2. act with confidence Report Overview In this report, ISR provides insight into the clinical trial regulation and development environment, sponsor and service provider activities, and population “health status” for Brazil. Methodologies: ISR gathered content for this report via an exhaustive secondary research effort and from company profile questionnaires that were distributed to CROs profiled in this report. 56 Charts and Graphs Q1, 2014 Report Structure: 1. Introduction 2. Brazilian Health Statistics 3. Clinical Trial Overview and Trial Metrics 4. Profile of Domestic Clinical Service Providers 5. Brazil Pharma/CRO Associations 6. International CROs Operating in Brazil Publication Date 79 Pages Valuable for: Clinical Operations, Medical Directors, Patient Recruitment, Site Selection, Portfolio Management What you will learn in this report: • How population health status, regulations and clinical trial activity, and international and domestic company partnerships make Brazil one of the top emerging global pharmaceutical markets • Insights from domestic service provider organizations on conducting clinical trials in Brazil • Clinical trial operational metrics for Brazil-only clinical studies • Compiled lists and contact details for domestic and international service providers in Brazil How you can use this report: • Understand how Brazil compares to other countries on a variety of health condition scales so the reader can best consider the areas in which Brazil may be beneficial as a trail site • Understand the legal, logistical, and regulatory details for conducting Brazilian trials, and illustrate the benefits and drawbacks of conducting trials in Brazil NEXT: Table of Contents and Sample Pages www.ISRreports.com ©2014 | Preview of: Brazil Clinical Development Profile 2
  • 3. act with confidence Table of Contents For table of contents and additional sample pages, download the full preview from our website: http://www.isrreports.com/product/brazil-clinical-development-profile/ www.ISRreports.com ©2014 | Preview of: Brazil Clinical Development Profile 3
  • 4. act with confidence Sample Page Introduction act with confidence Introduction Brazil’s population is approximately 200 million and represents enormous potential for the Welcome to ISR’s second Investigator Payments report highlighting Europe’s clinical pharmaceutical industry. The country is beginning to build a better understanding of clinical trial compensation. In this report, ISR wanted to gain a reputation for high-quality trials and biodiversity, and is attracting multinational pharmaceutical companies as it continues what drives investigator payments so that sponsors and CROs can benchmark their to develop its domestic providers as well. payment levels and better plan for study costs. According to IMS Health’s Medicines Outlook Through 2016 Report, the pharmaceutical marDeterminants of investigator payments come in many forms such as therapeutic ket in Brazil has experienced, on average, a 15.6% compound annual growth rate (CAGR) from area, compound orientation, trial complexity, and patient needs. Is there a one-size2007-2011. IMS forecasts that Brazil will experience a CAGR of 12-15% from 2012-2016. It is fits-all formula that can be applied uniformly across studies to produce the most also estimated that Brazil’s pharmaceutical spend per capita will be $180. effective compensation plan? Perhaps not, but by using this array of compensation averages pharmaceutical personnel and by understanding their non-monetary The Brazilianprovided by site market does pose a number of challenges due to its diverse motivations for for participation, planning to a sponsor or CRO can recruit and nature. A challengetrial foreign playersISR believes enter the market is the legal framework of the country. This forces thewithout breaking the budget. local companies, resulting in profit retain high quality sites companies into partnering with and control sharing. The legal and regulatory framework for patents is limited, leading to a lack of protection for intellectual property rights. In the process of writing this report, ISR reached out the CROs profiled in this report. Questionnaires were sent to contacts within these companies that asked questions regarding the company’s profile, the benefits and shortcomings of conducting trials in Brazil, and trends they’ve noticed in those planning to outsource clinical studies in Brazil. Not all of the CROs profiled in this report provided answers to the questionnaire that was sent. The complete responses from the CROs that responded are included in their entirety in this report. However, there were a few trends ISR noticed in the responses that we believe are worth highlighting in this portion of the report. Primarily, ISR noticed that regulatory related concerns are the primary concerns respondents voiced with regard to conducting clinical trials in Brazil. The question posed by ISR was: “What are the challenges in conducting a trial in Brazil?” Some of the responses received are shown below: “The main challenge is to improve regulatory submission timelines.” “Regulatory approvals timing” “The current regulatory scenario shows that depending on the project type it could take around 7-9 months for having the study approved by all required regulatory agencies (CEP, CONEP and ANVISA).” Timeline issues are typically a main concern in clinical research and, within the Brazilian contract research market, regulatory issues are a major factor contributing to timeline delays. Respondents from the domestic Brazilian CROs realize regulatory delays associated with conducting clinical trials in Brazil are substantial and often reach out to clients to make them aware of the delays that could be experienced. www.ISRreports.com ©2014 | Benchmarking European Investigator Payments 6 www.ISRreports.com ©2014 | Preview of: Brazil Clinical Development Profile This is a site-wide license and this file is not to be distributed beyond the terms of this agreement. For information on the license holder, please contact ISR (info@ISRreports.com). 4
  • 5. act with confidence Sample Page Brazil Health Statistics act with confidence Female breast cancer incidence Female breast cancer incidence The following chart, from the Health at a Glance OECD 2011 report, shows ageThe following chart, from the Health at a Glance OECD 2011 report, shows age-standardized female standardized incidence rates, 2009 (or nearest year). Brazil reports a rate of 42.3 breast cancer female breast cancer incidence rates, 2009 (or nearest year)� Brazil per 100,000 females. This number isof 42�3 than100,000 females� This 71.6. reports a rate lower per the OECD average of number is lower than the OECD average of 71�6� 109.4 Belgium France Israel Netherlands Ireland New Zealand Switzerland Denmark United Kingdom Finland Italy Iceland Australia Canada Sweden Luxembourg Germany Norway United States OECD Austria Czech Republic Slovenia Spain Portugal Hungary Slovak Republic Estonia Poland Greece Russian Federation Japan Brazil South Africa Chile Korea Indonesia Turkey Mexico India China 99.7 96.8 96.8 93.9 89.4 89.4 89.1 87.9 86.6 86.3 86.2 84.8 83.2 82.7 82.3 81.8 76.2 76.0 71.6 69.9 67.7 65.5 61.0 60.0 57.9 53.4 50.2 48.9 44.9 43.2 42.7 42.3 41.0 40.1 38.9 36.2 28.3 27.2 22.9 21.6 ©2014 Industry Standard Research 0 20 40 60 80 100 Age-standardized rates per 100,000 population 120 www.ISRreports.com ©2014 | Brazil: Clinical Development Profile 13 www.ISRreports.com ©2014 | Preview of: Brazil Clinical Development Profile This is an enterprise-wide license and this file is not to be distributed beyond the terms of this agreement. For information on the license holder, please contact ISR (info@ISRreports.com). 5
  • 6. act with confidence Sample Page Clinical Trial Overview act with confidence Regulatory overview According to SOMO’s Putting Contract Research Organisations on the Radar, the Brazilian regulatory agency ANVISA or Agência Nacional de Vigilância Sanitária (the Brazilian equivalent of the United States FDA) changed the regulatory process to expedite the regulatory approval of multicenter clinical trials in 2009� Today, only local Putting Contract of the coordinator sites have to ethics committeesResearch Organisations on the Radarapprove the study instead of all local ethics committees that have jurisdiction over each investigative site involved� After this approval is granted, the National Ethics Committee (CONEP) and ANVISA are approached simultaneously for approval� ANVISA is also the agency that gives approval for importation� The choice of on coordinator site is no crucial as requirements to disclose the SOMO also goes the to reveal there arenowregulatory the approval for all investigators sites is now in the hands the contracts between the sponsors of the study and new legislation conditions of of one local ethics committee. If used appropriately, thethe CROs, or should not weaken the protection of clinical trial investigators, to the ethics interview, a member of the between the sponsors and the principalparticipants. However, in an committees� National Ethics to the conditions but it is not used emphasised the need to ANVISA has accessCommission expressed concern and to evaluate whether the monitor the 125 implementation of the new process. The interviews with CROs indicate contractual arrangements protect the rights of the research participants� that the speed of proposal approval by the ethics committees is an important decisive factor in selecting the 126 coordinating centre. SOMO’s Brazil regulatory flowchart Figure 5: Regulatory flowchart – Brazil Source: Business Insights. 127 Source: SOMO The first Brazilian regulation that mentions the word CRO (known as ORCP in Brazil) is the RDC number 39, which was approved on 5 July 2008. This regulation defines the concept of CRO and its obligations. Like in Argentina, the only requirement is that the Clinical Development Profile to operate, www.ISRreports.com ©2014 | Brazil: CROs obtain a license 27 as any other health provider. ANVISA does not register a CRO until they present a project to the www.ISRreports.com ©2014 | Preview of: Brazil Clinical Development Profile regulatory agency. This is an enterprise-wide license and this file is not to be distributed beyond the terms of this agreement. For information on the license holder, please contact ISR (info@ISRreports.com). Contrary to the situation in Argentina, there is no obligation to disclose the conditions of the 6
  • 7. act with confidence Sample Page For table of contents and additional sample pages, download the full preview from our website: http://www.isrreports.com/product/brazil-clinical-development-profile/ www.ISRreports.com ©2014 | Preview of: Brazil Clinical Development Profile 7
  • 8. act with confidence Ordering Information For pricing and ordering information, please visit our website: http://www.isrreports.com/product/brazil-clinical-development-profile/ Save on this, or any ISR report, by registering a free account Register now • Receive a $250 instant credit towards any ISR report • Earn 10% credit towards all future purchases • Receive advanced notifications on ISR’s latest reports and free resources About Industry Standard Research Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services industries.  With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise.    For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at www. ISRreports.com, email info@ISRreports.com, or follow us on twitter @ISRreports. www.ISRreports.com ©2014 | Preview of: Brazil Clinical Development Profile 8
  • 9. The ISR Difference act with confidence Custom-quality syndicated market research www.ISRreports.com ISR's Reports vs. The Common Syndicated Report How confident are you? Research methods Mostly primary research; always appropriate for the topic vs. vs. One size fits all; usually publically available data Data Collection ISR's proprietary data collection tools and channels support fast, high quality data collection vs. Struggle to recruit the right targets and enough of them Respondents Sophisticated screening ensures genuine decision-makers vs. Undisclosed methodologies and respondent demographics Sample Sizes Robust sample sizes that instill confidence vs. Often insufficient industry representation that leaves you defending results Analysts Decades of experience means more insights that are immediately usable vs. vs. Junior analysts capable of reporting numbers www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Profile www.ISRreports.com ©2014 | Preview of: Brazil Clinical Development Functions 9